SMLR - Semler Scientific, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
39.50
+0.01 (+0.03%)
At close: 1:16PM EDT
Stock chart is not supported by your current browser
Previous Close39.49
Open39.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range39.50 - 39.98
52 Week Range25.50 - 54.50
Volume853
Avg. Volume14,364
Market Cap256.749M
Beta (3Y Monthly)0.67
PE Ratio (TTM)42.89
EPS (TTM)0.92
Earnings DateOct 24, 2019 - Oct 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research

    SMLR: Q2 Beats Big. Thesis Continues To Play Out. Upward Revision to CF Estimate Moves PT to $55

    The company did not hold an earnings call as CEO Doug Murphy-Chutorian continues to recover from the mild stroke he suffered approximately six weeks prior. Encouragingly, the Q2 earnings release notes that Doug continues to make strong progress, that SMLR will host a Q3 earnings call and that additional executives will join him on the call. As it relates to Q2 results, pretty much the whole income statement was a highlight.

  • PR Newswire

    Semler Reports Record Second Quarter and First Half 2019 Financial Results

    2019 Q2 HIGHLIGHTS compared to the corresponding period of 2018: - Revenues were $7,953,000 , an increase of 45% - Net income grew to $0.41 per basic share and $0.32 per diluted share, compared to $0.24 ...

  • PR Newswire

    Semler to Report Second Quarter and First Half 2019 Financial Results on July 26, 2019

    SAN JOSE, Calif., July 16, 2019 /PRNewswire/ -- Semler Scientific, Inc. (SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the second quarter and first half ended June 30, 2019 before the open of U.S. financial markets on Friday, July 26, 2019. Semler will not host an investor call for this quarter as Chief Executive Officer, Doug Murphy-Chutorian, M.D. continues his recovery from a mild stroke.  Semler anticipates that it will host a conference call to discuss financial results for the third quarter and first nine months of 2019.

  • Zacks Small Cap Research

    SMLR: No Business Interruptions Result from CEO Doug Murphy-Chutorian’s Mild Stroke

    On June 17th, Semler (SMLR) announced that while CEO Doug Murphy-Chutorian suffered a mild stroke following elective surgery, he continues to lead the company and the incident did not result in any interruptions to the business. As such, we continue to reiterate our comments from our recent earnings updates… the consistency and regularity of revenue growth and flatness of expenses lend credence to the validity of the company’s business model and strategy. Much of that hinges on the supposition that insurers have an economic interest in paying for their capitation-based insured to be tested for PAD.

  • PR Newswire

    Semler Scientific, Inc.'s CEO Continues Recovery From Mild Stroke

    SAN JOSE, Calif. , June 17, 2019 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency ...

  • Zacks Small Cap Research

    SMLR: No Slowing Down Into 2019. Record Revenue, EPS. Cash Flow Churning. Moving PT to $50/share

    Meanwhile, operating expenses (not including cost of revenue) were at an all-time high but inline with our $4.0M estimate and a record low on a percentage of sales basis. Perhaps just as important as the new records that were set on the top and bottom lines was that significant cash generation continues (Q1 cash flow statement will be available when the 10-Q is filed). Semler generated positive cash flow from operations in every quarter in 2018.

  • PR Newswire

    Semler Reports First Quarter 2019 Financial Results

    2019 Q1 HIGHLIGHTS compared to the corresponding period of 2018: - Revenue was $6,761,000 , which is an increase of 51% - Net income grew to $0.29 per basic share and $0.23 per diluted share, compared ...

  • PR Newswire

    Semler to Report First Quarter 2019 Financial Results and Host Conference Call on April 29, 2019

    SAN JOSE, Calif. , April 18, 2019 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency ...

  • Zacks Small Cap Research

    SMLR: Revenue, Earnings & Cash Flow Continue to Climb. Cash Flow Forecast Implies $45/Share Fair Value

    Q4 2018 Results: Revenue, Earnings & Cash Flow Continue to Climb. Semler (SMLR) reported financial results for the fourth quarter ending December 31, 2018. While revenue slightly missed our estimate, it nonetheless came in strong – up 42% yoy, 7% better than Q3 and a new record high.

  • PR Newswire

    Semler Reports Fourth Quarter and Year End 2018 Financial Results

    2018 HIGHLIGHTS compared to 2017: - Annual revenue increased by 73% - Net income after tax grew to $0.82 per basic share and $0.66 per diluted share, compared to a net loss of $0.28 per basic and diluted ...

  • PR Newswire

    Semler to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on February 27, 2019

    SAN JOSE, Calif., Feb. 14, 2019 /PRNewswire/ -- Semler Scientific, Inc. (SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for fourth quarter and full year ended December 31, 2018 before the open of U.S. financial markets on Wednesday, February 27, 2019. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 11 a.m. ET the same day. Please specify to the operator that you would like to join the "Semler Fourth Quarter and Year End 2018 Financial Results Call, conference ID#: 3068129." The conference call will be archived on Semler's website at www.semlerscientific.com.

  • Zacks Small Cap Research

    SMLR: Revenue up 55%, cash flow continues to churn, balance sheet cleaned, moving PT to $35/share

    Net income and EPS through the first nine months of the year was $3.6M and $0.48, compared to a $1.8M net loss and ($0.33) EPS in the comparable prior year period. Each of the last several consecutive quarters’ financial results has incrementally bolstered the likely long-term viability of Semler’s business model and sustainability of growth of revenue/earnings/cash flow-generation.

  • GuruFocus.com

    US Market Indexes Close Lower on Friday

    Nasdaq Composite closes at 7,167.21 for a loss of -2.06%

  • PR Newswire

    Semler to Report Third Quarter and First Nine Months of 2018 Financial Results and Host Conference Call on October 26, 2018

    SAN JOSE, Calif. , Oct. 16, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology and software solutions to improve the clinical effectiveness ...